Imatinib
- CAS No.
- 152459-95-5
- Chemical Name:
- Imatinib
- Synonyms
- Imatinib Mesilate;matinib;4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE;lmatinib;IMATINIB-D3;IMA-3;Veenat;ST-1571;CS-1955;IMATINIB
- CBNumber:
- CB7370890
- Molecular Formula:
- C29H31N7O
- Molecular Weight:
- 493.6
- MDL Number:
- MFCD05662257
- MOL File:
- 152459-95-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Imatinib >98.0%(HPLC) | I0906 | 100mg | $46 |
| Imatinib >98.0%(HPLC) | I0906 | 1g | $138 |
| IMATINIB 97% | 63169 | 5G | $27 |
| IMATINIB 97% | 63169 | 25G | $59 |
| Imatinib base | FM10813 | 0.025kg | $249.81 |
| More product size | |||
| Melting point | 208-210°C (dec.) |
|---|---|
| Density | 1+-.0.06 g/cm3(Predicted) |
| storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| solubility | DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
| pka | pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃) |
| form | Solid |
| color | White to Pale Beige |
| Merck | 14,4902 |
| InChIKey | KTUFNOKKBVMGRW-UHFFFAOYSA-N |
| SMILES | C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)(=O)C1=CC=C(CN2CCN(C)CC2)C=C1 |
| CAS DataBase Reference | 152459-95-5(CAS DataBase Reference) |
| FDA UNII | BKJ8M8G5HI |
| ATC code | L01EA01 |
| UNSPSC Code | 12352200 |
| NACRES | NA.21 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335-H361fd | |||||||||
| Precautionary statements | P261-P271-P280 | |||||||||
| Safety Statements | 24/25 | |||||||||
| WGK Germany | WGK 3 | |||||||||
| RTECS | CV5585673 | |||||||||
| HS Code | 29339900 | |||||||||
| Storage Class | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
|||||||||
| Hazard Classifications | Carc. 2 Lact. Muta. 2 Repr. 1B |
|||||||||
| REACH Registrations | Active | |||||||||
| NFPA 704 |
|
Imatinib price More Price(125)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| TCI Chemical | I0906 | Imatinib >98.0%(HPLC) | 152459-95-5 | 100mg | $46 | 2026-04-30 | Buy |
| TCI Chemical | I0906 | Imatinib >98.0%(HPLC) | 152459-95-5 | 1g | $138 | 2026-04-30 | Buy |
| AstaTech | 63169 | IMATINIB 97% | 152459-95-5 | 5G | $27 | 2026-04-30 | Buy |
| AstaTech | 63169 | IMATINIB 97% | 152459-95-5 | 25G | $59 | 2026-04-30 | Buy |
| Biosynth | FM10813 | Imatinib base | 152459-95-5 | 0.025kg | $249.81 | 2026-06-04 | Buy |
Imatinib Chemical Properties,Uses,Production
Product description
Imatinib is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.
CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
Imatinib is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.
Binding Mode
Imatinib binds with high specificity to an inactive form of the ABL kinase, resulting in high kinase selectivity. Interestingly, the N-methylpiperazine group, which was installed to increase solubility, also interacts strongly with ABL via hydrogen bonds to the backbone carbonyl group of Ile360 and His361. The co-crystal structure of imatinib with ABL shows additional four hydrogen bonds between (1) the pyridine ring N atom and the backbone NH of Met318 in the hinge region; (2) the anilino NH and the side chain of the gatekeeper ;residue Thr315; (3) the amide NH and the side chain of Glu286 from helix C; and (4) the amide carbonyl and the backbone NH of Asp381 (Fig. 4). The hydrogen bonds are also complemented by extensive hydrophobic interactions over the whole length of the inhibitor except the N-methylpiperazine region which is partially exposed to solvent.
Approved indications in Europe, the United States and other countries
Novartis's imatinib (imatinib, Glivec) had been approved in Switzerland for being used as first-line drug for the treatment of early-stage adult chronic myelogenous leukemia and can also be applied to patients with various types of chronic granulocytic leukemia. Switzerland is the first countries which had approved to additionally include the above two indications of this drug.
On July 28, 2006, the European Agency for the Evaluation of Medicinal Products (EMEA) had recommended the imatinib (Gleevec) of the Novartis Company for the treatment of two new indications-dermatofibrosarcoma protuberans (DFSP) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). These final approvals of these two indications still need to wait the decision of the European Food and Drug Administration.
In addition, Novartis has announced that the application of imatinib in treating hypereosinophilic syndrome and systemic mastocytosis is still in the approval process of FDA and EMEA.
The drug has currently been approved in Europe, the United States and other countries for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and gastrointestinal stromal tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Precautions
When combined with Ketoconazole, itraconazole, erythromycin, clarithromycin, the Cmax of this drug can (the maximum plasma concentration after the first drug administration) be increased by an average of 26% with the AUC being increased by 40%.
The inducers of the metabolizing enzyme of hepatic drugs such as dexamethasone, phenytoin, carbamazepine, rifampicin and barbiturates can significantly reduce blood concentration of the drug.
When the CYP3A4 metabolized substrates such as simvastatin, cyclosporine, pimozide, etc. were used in combined with imatinib, the plasma concentration of those drugs can be increased due to its competing with the drug enzyme.
Uses
Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.
Chemical Properties
Orange Solid
Uses
Imatinib impurity.
Uses
antineoplastic
Uses
Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
Uses
atypical antipsychotic
Uses
Targeting constitutive BCR::ABL1 kinase activity with tyrosine kinase inhibitors (TKIs), beginning with imatinib, has transformed CML management and substantially improved long-term survival.[2]
Definition
ChEBI: Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It is functionally related to a benzamide.
Indications
Imantinib mesylate (Gleevec) is a rationally designed inhibitor of the tumor-specific bcr-abl kinase. The Philadelphia chromosome, present in nearly all patients with chronic myelogenous leukemia (CML), is produced by a chromosomal rearrangement linking the bcr and the abl genes. The bcr-able kinase is therefore a unique drug target in leukemic cells, and imantinib selectively and potently inhibits this kinase. Remissions in CML patients are achieved with high frequency and very low toxicity, and this compound may become a front-line agent for treating this cancer. Unfortunately, drug resistance has already been observed in the clinic as a result of mutations in the bcr-abl kinase, and this magic bullet does not appear to be curative for CML patients. Extension of the use of imantinib to other tumor types with overexpression of c-kit kinase or platelet-derived growth factor kinase is undergoing development because of its observed activity against these kinases.
Indications
Bcr-Abl inhibitor imatinib (Gleevec(R), Novartis) was approved in 2001 by the FDA. Although fasudil was approved in 1995, imatinib is widely perceived as the first approved SMKI mainly owing to the fact that fasudil's kinase inhibitory mechanism was unknown at the time of approval, and efforts to gain approval of fasudil have been unsuccessful in the United States and Europe.
The field of kinase inhibitor development has evolved rapidly since the approval of imatinib. Some of the key discoveries and events include (i) the discovery of MAPK/ERK inhibitors, for example, CI-1040 (PD184352), as the first series of type III inhibitors in 2003; (ii) the approval of first dual tyrosine kinase and serine/threonine kinase inhibitor sorafenib in 2005; (iii) the description of the first series of allosteric type IVkinase inhibitor, that is,GNF-2 and analogues that inhibit Bcr–Abl through an allosteric non-ATP-competitivemode, by Gray and coworkers in 2006; (iv) the approval of the first type III inhibitor trametinib in 2013; (v) the approval of the first covalent kinase inhibitors, afatinib and ibrutinib, in 2013; and (vi) the approval of the first lipid kinase inhibitor, that is, the PI3K inhibitor idelalisib, in 2014.
By December 2016, kinase inhibitor drug discovery can leverage the structures of over 200 human kinases and 5000 kinases of all types, over 1 million publications, clinical data from more than 200 molecules currently in phase I–III trials, and post-marketing results from the approved 38 drugs.
Synthesis Reference(s)
[1] Synthesis of Imatinib by C–N Coupling Reaction of Primary Amide and Bromo-Substituted Pyrimidine Amine. Org. Process Res. Dev. 2019, 23, 9, 1918–1925
General Description
non-receptor tyrosine kinase|
Treatment: CML, ALL, GIST
Oral bioavailability = 98%
Elimination half-life = 20 h
Protein binding = 95%
Biological Activity
imatinib is an inhibitor of protein-tyrosine kinase with ic50 values of 0.1, 0.1 and 0.025μm, respectively against pdgf receptor, c-kit and abl [1].the type 3 group of receptor tyrosine kinases includes pdgfr, csf-1r, flt-3, c-kit and so on. pdgfrs are found in normal tissues, cells as well as some tumors. it is associated with several nonmalignant proliferative diseases. in vitro assays show that imatinib can inhibit both pdgf-aa and pdgf-bb stimulated pdgf receptor phosphorylation. imatinib is also found to inhibit the phosphorylation of c-kit, another kinase which mediates the growth of a number of tumors. imatinib inhibits the phosphorylation of these kinases without effecting the expression of them. some other kinases of the type 3 group (such as fms and flt-3) can’t be inhibited by imatinib, suggesting a selectivity of imatinib. in addition, imatinib is shown to significantly inhibit the bcr-abl tyrosine kinase both in cell-based assay and in vitro kinase assay. moreover, as a downstream pathway of pdgf-mediated signals, map kinase activation can also be effected in rat a10 smooth muscle cells [1].
Clinical Use
Tyrosine kinase inhibitor, antineoplastic agent:
Treatment of chronic myeloid leukaemia
Treatment of metastatic malignant gastrointestinal
stromal tumours
Treatment of acute lymphoblastic leukaemia
Synthesis
Cuiling Wang and colleagues reported a method for imatinib synthesis[1]. It is described by using the C–N coupling reaction of 4-(4-methylpiperazine-1-methyl)benzamide with N-(5-bromo-2-tolyl)-4-(3-pyridyl)pyrimidin-2-amine to form imatinib. In this synthetic route, the high efficiency and high selectivity of nano-ZnO as a catalyst is key to the mild hydrolysis of 4-(4-methylpiperazine-1-methyl)benzonitrile into the corresponding amide. The total imatinib yield was 51.3%, and the purity was 99.9%.
target
PDGF receptor
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: concentration reduced by rifampicin
- avoid.
Anticoagulants: enhanced anticoagulant effect of
warfarin, replace with heparin.
Antidepressants: concentration reduced by St. Johns
Wort - avoid.
Antiepileptics: concentration reduced by
carbamazepine, fosphenytoin, oxcarbazepine and
phenytoin - avoid; absorption of phenytoin possibly
reduced.
Antipsychotics: avoid concomitant use with
clozapine (increased risk of agranulocytosis).
Antivirals: avoid with boceprevir.
Ciclosporin: may increase ciclosporin levels.
Cytotoxics: possibly increases bosutinib
concentration - avoid or reduce bosutinib dose;
concentration of everolimus and possibly ibrutinib
increased - reduce dose of everolimus and ibrutinib.
Tacrolimus: may increase tacrolimus levels.
Metabolism
The main circulating metabolite in humans is the N-demethylated piperazine derivative, which shows similar in vitro potency to the parent. Imatinib and the N-demethyl metabolite together accounted for about 65% of the circulating radioactivity (AUC(0-48h)). The remaining circulating radioactivity consisted of a number of minor metabolites. In vitro results showed that CYP3A4 was the major human P450 enzyme catalysing the biotransformation of imatinib. Based on the recovery of compound(s) after an oral [14C]-labelled dose of imatinib, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder being metabolites.
Mode of action
Imatinib binds close to the ATP-binding site of BCR-ABL and locks it in a closed inactive conformation which excludes ATP. This shuts down its sustained signaling, thus blocking leukemic cell growth.
Background
Imatinib is a tyrosine kinase inhibitor that is a relatively specific ATP-binding site antagonist of Bcr-Abl, PDGF receptor, and c-Kit TKs. Results are encouraging in chronic myeloid leukemia clinical trials and imatinib has become a paradigm for targeted cancer therapeutics. Signal transduction through phospho-tyrosine pathways has been studied extensively, and tyrosine phosphorylation has been linked to multiple cell growth and differentiation pathways. Because the observed leukemic state of CML is dependent on the intact Bcr-Abl tyrosine kinase activity, extensive work has been done to identify substrates of Bcr-Abl and thus possible mechanisms leading to a myeloid expansion. Many groups have characterized prominent tyrosine-phosphorylated protein substrates in both CML blasts and Bcr-Abl-expressing cell lines, including SHIP, c-Cbl, Dok, Shc, and CrkL. In addition, key signal transduction pathways involving PI3 kinase, Ras, Myc, and Stat5 are also activated in a Bcr-Abl kinase-dependent manner.
References
[1] elisabeth buchdunger, catherine l. cioffi, norman law, david stover, sayuri ohno-jones, brian j. druker and nicholas b. lydon. abl protein-tyrosine kinase inhibitor sti571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. the journal of pharmacology and experimental therapeutics. 2000, 295(1): 139-145.
[2] Marisol Miranda-Galvis. (2026). Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysis. Blood Cancer Journal, 17 2 1. https://doi.org/10.1038/s41408-026-01485-z
Imatinib Preparation Products And Raw materials
Raw materials
1of2
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| HANGZHOU LEAP CHEM CO., LTD. | +86-571-87711850 | market18@leapchem.com | China | 24597 | 58 |
| Hebei Chuanghai Biotechnology Co., Ltd | +8615350571055 | Sibel@chuanghaibio.com | China | 8738 | 58 |
| HangZhou RunYan Pharma Technology Co.,LTD. | +8618882027439 | sales2@runyanpharma.com | China | 302 | 58 |
| Nanjing Fred Technology Co., Ltd | +86-25-84696168 +86-15380713688 | Austin@fredbio.com | China | 2428 | 58 |
| Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 | info@fdachem.com | China | 20120 | 58 |
| Hangzhou Hyper Chemicals Limited | +86-0086-57187702781 +8613675893055 | info@hyper-chem.com | China | 310 | 58 |
| HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD | +86-15350851019; +8615350851019 | admin@86-ss.com | China | 999 | 58 |
| Moxin Chemicals | +86-17320513646 +8617320513646 | anna@molcoo.com | China | 10000 | 58 |
| Wuhan JiyunZen Tech Co., Ltd. | +86-18062099985 | Amyjiyunzen@yeah.net | China | 672 | 58 |
| Sinoway Industrial co., ltd. | +86-0592-5800732 +86-13806035118 | xie@china-sinoway.com | China | 1369 | 58 |
Related articles
- Imatinib: Targeted Tyrosine Kinase Inhibitor Transforming Cancer Treatment
- Imatinib revolutionizes CML treatment by blocking leukemic cell proliferation, showing durable responses and long-term surviva....
- Jun 20，2025
View Lastest Price from Imatinib manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-23 | Imatinib
152459-95-5
|
$900.00-999.00 | 99% | 5000 | HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD | ||
 |
2026-07-23 | Imatinib
152459-95-5
|
1KG | 99%min | 100kg | WUHAN FORTUNA CHEMICAL CO., LTD | ||
 |
2026-07-22 | Imatinib
152459-95-5
|
$36.00-79.00 | 99.95% | 10g | TargetMol Chemicals Inc. |
